PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 6112人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1255056, encodeId=6a3b1255056fc, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=患者招募：恒瑞PD-L1药物SHR-1316或安慰剂联合化疗围手术期治疗非小细胞肺癌临床研究, objectType=article, longId=192612, objectId=2f0719261224, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f0719261224, replyNumber=0, likeNumber=107, createdTime=2020-04-22, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f0719261224, moduleTitle=患者招募：恒瑞PD-L1药物SHR-1316或安慰剂联合化疗围手术期治疗非小细胞肺癌临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f0719261224)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255055, encodeId=be291255055ed, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JTO：默克PD-L1双特异性抗体显神威，1期结果显示在NSCLC的ORR可达36%, objectType=article, longId=192587, objectId=6b7419258e79, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b7419258e79, replyNumber=0, likeNumber=85, createdTime=2020-04-22, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b7419258e79, moduleTitle=JTO：默克PD-L1双特异性抗体显神威，1期结果显示在NSCLC的ORR可达36%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b7419258e79)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255054, encodeId=df04125505465, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet Onocol：NSCLC脑转移的免疫治疗依赖PD-L1表达, objectType=article, longId=191515, objectId=c8b119151594, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8b119151594, replyNumber=0, likeNumber=50, createdTime=2020-04-07, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8b119151594, moduleTitle=Lancet Onocol：NSCLC脑转移的免疫治疗依赖PD-L1表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8b119151594)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255053, encodeId=1a9a1255053ad, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗, objectType=article, longId=191241, objectId=eff619124151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eff619124151, replyNumber=0, likeNumber=65, createdTime=2020-04-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eff619124151, moduleTitle=FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eff619124151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255052, encodeId=dcc7125505286, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Brit J Cancer：PD-L2和PD-L1表达在食管癌患者中预后和临床意义, objectType=article, longId=190841, objectId=909219084165, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=909219084165, replyNumber=0, likeNumber=87, createdTime=2020-03-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=909219084165, moduleTitle=Brit J Cancer：PD-L2和PD-L1表达在食管癌患者中预后和临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=909219084165)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255051, encodeId=4dec1255051d8, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！, objectType=article, longId=189361, objectId=9e5418936139, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e5418936139, replyNumber=0, likeNumber=82, createdTime=2020-03-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e5418936139, moduleTitle=不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e5418936139)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255050, encodeId=2b0f12550509a, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=喜大普奔！中国PD-L1免疫疗法惠及III期肺癌患者，5年生存率或超50%, objectType=article, longId=189360, objectId=4814189360cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4814189360cb, replyNumber=0, likeNumber=72, createdTime=2020-03-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4814189360cb, moduleTitle=喜大普奔！中国PD-L1免疫疗法惠及III期肺癌患者，5年生存率或超50%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4814189360cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255049, encodeId=eee3125504982, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq在美国获得优先审查, objectType=article, longId=188787, objectId=ec53188e8791, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec53188e8791, replyNumber=0, likeNumber=66, createdTime=2020-02-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec53188e8791, moduleTitle=罗氏的PD-L1单抗Tecentriq在美国获得优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec53188e8791)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255048, encodeId=e602125504874, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=ARCH PATHOL LAB MED：使用程序性死亡配体-1 (PD-L1)染色可从良性间皮反应中分离肉瘤样恶性间皮瘤？, objectType=article, longId=187731, objectId=179b18e7319d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=179b18e7319d, replyNumber=0, likeNumber=53, createdTime=2020-02-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=179b18e7319d, moduleTitle=ARCH PATHOL LAB MED：使用程序性死亡配体-1 (PD-L1)染色可从良性间皮反应中分离肉瘤样恶性间皮瘤？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=179b18e7319d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255047, encodeId=58ac125504e41, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Sci Rep：膀胱泌尿系肿瘤中PD-L1和其他免疫标记的评估, objectType=article, longId=187690, objectId=31ac18e6909a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31ac18e6909a, replyNumber=0, likeNumber=66, createdTime=2020-02-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31ac18e6909a, moduleTitle=Sci Rep：膀胱泌尿系肿瘤中PD-L1和其他免疫标记的评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31ac18e6909a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255046, encodeId=31a21255046bb, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Gastroenterology：PD-L1表达对原发性胃和肠弥漫性大B细胞淋巴瘤的预后影响, objectType=article, longId=187601, objectId=3fc418e60132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fc418e60132, replyNumber=0, likeNumber=65, createdTime=2020-02-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fc418e60132, moduleTitle=J Gastroenterology：PD-L1表达对原发性胃和肠弥漫性大B细胞淋巴瘤的预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fc418e60132)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255045, encodeId=81201255045d2, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JAMA Oncol：惊人发现！癌症患者越胖，PD-L1抑制剂疗效越好, objectType=article, longId=185982, objectId=c09b18598237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c09b18598237, replyNumber=0, likeNumber=81, createdTime=2020-01-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c09b18598237, moduleTitle=JAMA Oncol：惊人发现！癌症患者越胖，PD-L1抑制剂疗效越好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c09b18598237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255044, encodeId=77431255044c3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, objectType=article, longId=185843, objectId=5f5518584350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f5518584350, replyNumber=0, likeNumber=65, createdTime=2020-01-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f5518584350, moduleTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f5518584350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255043, encodeId=96bf1255043db, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Brit J Cancer：晚期尿路上皮癌中结合临床和基因组因素的模型预测对PD-1/PD-L1阻断的响应, objectType=article, longId=185696, objectId=1fd2185696f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fd2185696f8, replyNumber=0, likeNumber=83, createdTime=2020-01-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fd2185696f8, moduleTitle=Brit J Cancer：晚期尿路上皮癌中结合临床和基因组因素的模型预测对PD-1/PD-L1阻断的响应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fd2185696f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255042, encodeId=db5c1255042fc, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌, objectType=article, longId=185527, objectId=8ca718552e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ca718552e25, replyNumber=0, likeNumber=84, createdTime=2020-01-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ca718552e25, moduleTitle=因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ca718552e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255041, encodeId=eba412550415b, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JAMA Oncol：PD-L1抗体对肥胖的癌症患者疗效更好, objectType=article, longId=185352, objectId=d243185352a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d243185352a9, replyNumber=0, likeNumber=67, createdTime=2019-12-29, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d243185352a9, moduleTitle=JAMA Oncol：PD-L1抗体对肥胖的癌症患者疗效更好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d243185352a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255040, encodeId=6b69125504069, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq组合显着降低黑色素瘤患者的疾病进展和死亡风险, objectType=article, longId=184877, objectId=fe901848e7f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe901848e7f2, replyNumber=0, likeNumber=64, createdTime=2019-12-19, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe901848e7f2, moduleTitle=罗氏的PD-L1单抗Tecentriq组合显着降低黑色素瘤患者的疾病进展和死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe901848e7f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255039, encodeId=67541255039fe, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, objectType=article, longId=184290, objectId=431b184290f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=431b184290f9, replyNumber=0, likeNumber=74, createdTime=2019-12-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=431b184290f9, moduleTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=431b184290f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255038, encodeId=6e7a125503838, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=FDA授予阿斯利康的PD-L1单抗Imfinzi优先审查, objectType=article, longId=183990, objectId=e516183990ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e516183990ae, replyNumber=0, likeNumber=82, createdTime=2019-12-04, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e516183990ae, moduleTitle=FDA授予阿斯利康的PD-L1单抗Imfinzi优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e516183990ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255037, encodeId=1964125503e14, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上, objectType=article, longId=183550, objectId=84a4183550aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84a4183550aa, replyNumber=0, likeNumber=60, createdTime=2019-11-26, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84a4183550aa, moduleTitle=罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84a4183550aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

患者招募：恒瑞PD-L1药物SHR-1316或安慰剂联合化疗围手术期治疗非小细胞肺癌临床研究

2020-04-22

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JTO：默克PD-L1双特异性抗体显神威，1期结果显示在NSCLC的ORR可达36%

2020-04-22

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet Onocol：NSCLC脑转移的免疫治疗依赖PD-L1表达

2020-04-07

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

FDA批准阿斯利康的PD-L1单抗Imfinzi，用于广泛期小细胞肺癌的一线治疗

2020-04-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Brit J Cancer：PD-L2和PD-L1表达在食管癌患者中预后和临床意义

2020-03-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！

2020-03-06

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

喜大普奔！中国PD-L1免疫疗法惠及III期肺癌患者，5年生存率或超50%

2020-03-06

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏的PD-L1单抗Tecentriq在美国获得优先审查

2020-02-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

ARCH PATHOL LAB MED：使用程序性死亡配体-1 (PD-L1)染色可从良性间皮反应中分离肉瘤样恶性间皮瘤？

2020-02-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Sci Rep：膀胱泌尿系肿瘤中PD-L1和其他免疫标记的评估

2020-02-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Gastroenterology：PD-L1表达对原发性胃和肠弥漫性大B细胞淋巴瘤的预后影响

2020-02-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JAMA Oncol：惊人发现！癌症患者越胖，PD-L1抑制剂疗效越好

2020-01-11

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点

2020-01-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Brit J Cancer：晚期尿路上皮癌中结合临床和基因组因素的模型预测对PD-1/PD-L1阻断的响应

2020-01-06

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌

2020-01-03

heli0118 (审核中...)

前往app查看评论内容

#PD-L1#

JAMA Oncol：PD-L1抗体对肥胖的癌症患者疗效更好

2019-12-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏的PD-L1单抗Tecentriq组合显着降低黑色素瘤患者的疾病进展和死亡风险

2019-12-19

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌

2019-12-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

FDA授予阿斯利康的PD-L1单抗Imfinzi优先审查

2019-12-04

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上

2019-11-26

科室
- - 订阅+
  - 更多科室
工具
服务